| Date | Title |
| 12/21/06 | Depomed Receives $10 Million License Fee From Esprit and Withdraws Arbitration Proceeding |
| 12/20/06 | Depomed Announces Sweeping Interim Victory in Litigation Against IVAX |
| 12/18/06 | Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma |
| 12/12/06 | DepoMed Announces Strong Positive Phase II Trial Results for Once Daily Gabapentin GR ™ to Treat Symptoms of Diabetic Peripheral Neuropathy |
| 12/12/06 | Depomed Announces Equity Financing Commitment of Up to $30 Million |
| 12/04/06 | Depomed Comments on Today's Trading Activity |
| 11/21/06 | New Patient Support Program Offers Savings on Glumetza(TM) Therapy for Type 2 Diabetes |
| 10/26/06 | Depomed to Webcast Presentations at Two Healthcare Investment Conferences |
| 10/26/06 | Depomed to Announce Third Quarter 2006 Financial Results on Thursday, November 9, 2006 |
| 10/18/06 | Depomed Obtains Exclusive License to Gabapentin USE in Hot Flashes |
| 10/05/06 | Depomed Completes Enrollment in Phase II Clinical Trial in Diabetic Peripheral Neuropathy with Gabapentin GR |
| 09/20/06 | Depomed to Present at the UBS Global Life Sciences Conference |
| 09/18/06 | Depomed to Present at the Oppenheimer Diabetes Conference |
| 09/06/06 | New Once-Daily Oral Diabetes Treatment Glumetza(TM) Now Available |
| 09/05/06 | Depomed to Present at the Thinkequity Partners Growth Conference |
| 08/31/06 | Depomed to Present at the Thomas Weisel Partners Healthcare Conference |
| 08/23/06 | Depomed and King Pharmaceuticals Prepare for Launch of Glumetza(TM) as Timely, New ADA Guidelines are Issued; Consensus Statement Recommends That Metformin Be Added to Lifestyle Changes as Initial Treatment For Type 2 Diabetes |
| 08/15/06 | Depomed Announces Completion of Phase I Clinical Trial With Gastroesophageal Reflux Disease Compound; Phase IIA Clinical Trial Planned |
| 08/07/06 | DepoMed Reports Second Quarter 2006 Financial Results; Revenues Increase to $2.2 Million Compared to $428,000 in 2005 |
| 08/07/06 | Depomed Gains Greater Access to Global Pharmaceutical Companies Through Collaboration Agreement With Patheon; The Company Expands Reach to Maximize Value of Its Proprietary Technology |
| 07/28/06 | Depomed to Present at the Bank of America Specialty Pharmaceuticals Conference |
| 07/25/06 | Depomed to Announce Second Quarter 2006 Financial Results on Monday, August 7, 2006 |
| 07/24/06 | Depomed Takes Action to Support Momentum in Proquin(R) XR Sales; The Company Amends Marketing Agreement with Esprit Pharma |
| 07/24/06 | Depomed Provides Update on Esprit Pharma Agreement |
| 07/06/06 | DepoMed Names Matthew Gosling Vice President, Legal and General Counsel |
| 07/05/06 | Depomed to Present at the C.E. Unterberg Towbin Emerging Growth Conference |
| 06/29/06 | Depomed Unveils Data at the Endocrine Society Meeting Showing Significant Variability Between Generic Metformin Products |
| 06/28/06 | King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM) |
| 06/26/06 | Depomed Reports Dose Proportionality of Gabapentin GR at the Endocrine Society's Annual Meeting |
| 06/07/06 | Depomed Reports Published Data on Improved Glycemic Control in Patirnts with Type 2 Diabetes with Glumetza/Sulfonylurea Treatment Regimen |
| 06/02/06 | Depomed to Present at Needham & Company, LLC’s Fifth Annual Biotechnology and Medical Technology Conference |
| 05/10/06 | DepoMed Reports First Quarter 2006 Financial Results |
| 05/10/06 | DepoMed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR ™ |
| 05/08/06 | DepoMed to Present at the Bank of America Health Care Conference |
| 04/27/06 | DepoMed to Announce First Quarter 2006 Financial Results on Wednesday, May 10, 2006 |
| 04/26/06 | Depomed and Esprit Announce Availability of Proquin(R)XR 3-Tablet Blister Packs |
| 04/11/06 | Depomed Data Published in Diabetes Care on Glumetza, an FDA-Approved Treatment for Type II Diabetes |
| 03/30/06 | Depomed to Present at CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference |
| 03/29/06 | Depomed and Madaus S.R.L. Announce Acceptance of the Applcation for Approval of Proquin(R) XR in Sweden |
| 03/14/06 | DepoMed Reports 2005 Year End Financial Results; Significant Increase in Revenue Reported, Resulting from the Company’s Successful Partnering Activities and Royalties from First Product Sales |
| 02/28/06 | Depomed to Announce Fourth Quarter and Year end 2005 Financial Results on Tuesday, March 14, 2006 |
| 02/23/06 | Depomed Promotes Bret Berner, PH.D. to Chief Scientific Officer |
| 01/04/06 | Depomed Announces Positive Results of Phase II Clinical Trial for Gabapentin GR(TM) in Postherpetic Neuralgia |
